FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
What happened
FDA inspected Pharmathen's drug manufacturing facility in Greece from November 10 to 21, 2025. Investigators found smoke studies did not show unidirectional airflow, poor aseptic behavior, gram-negative microbes in ISO 5 air samples, inadequate room pressure differentials, missing facility monitoring records, and incomplete sterility test documentation.
What FDA found
FDA found the aseptic vial filling line's smoke studies did not show unidirectional airflow and observed poor aseptic practices that could contaminate sterile drugs.
21 CFR 211.113(b)Pharmathen did not thoroughly investigate sterility failures, environmental monitoring excursions, and visible particulate failures, and its corrective actions were not effective.
21 CFR 211.192The aseptic filling rooms had lower pressure than adjacent rooms, and facility monitoring data such as differential pressure, temperature, and humidity were not routinely recorded or stored.
21 CFR 211.42(c)(10)Microbial plates in incubators lacked raw data and sample identification, sterility test records were not controlled, and sterility tests for 16 batches were invalidated.
21 CFR 211.160(a)FDA found the quality system did not adequately ensure data accuracy and integrity.
What FDA wants
FDA asks Pharmathen to provide independent assessments, detailed remediation and CAPA plans, and retrospective reviews for aseptic operations, investigations, facility controls, laboratory records, and data integrity. The letter does not state a response deadline.
Who should pay attention
- companies that source sterile drug products from Pharmathen for the U.S. market
- U.S. distributors and importers of sterile injectable or powder products
- quality teams overseeing sterile manufacturing, environmental monitoring, and data integrity at suppliers
This is a summary. Read the original letter on fda.gov.